Teva Pharmaceutical Industries Limited (TLV:TEVA)
| Market Cap | 116.00B |
| Revenue (ttm) | 55.55B |
| Net Income (ttm) | 2.36B |
| Shares Out | n/a |
| EPS (ttm) | 2.04 |
| PE Ratio | 49.14 |
| Forward PE | 12.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,384,820 |
| Average Volume | 1,359,006 |
| Open | 10,130 |
| Previous Close | 10,080 |
| Day's Range | 10,000 - 10,170 |
| 52-Week Range | 4,865 - 10,240 |
| Beta | 0.67 |
| RSI | 76.96 |
| Earnings Date | Jan 28, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews
$100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
Teva Pharmaceutical Indus (NYSE: TEVA) has outperformed the market over the past 5 years by 13.95% on an annualized basis producing an average annual return of 27.15%. Currently, Teva Pharmaceutical ...
Teva Pharmaceutical Stock Hits 52-Week High On Credit Ratings Lift
S&P upgraded Teva to BB+ and Moody's turned ... Full story available on Benzinga.com
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody’s Ratings Agency Revises Outlook to Positive
The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline. Moody’s affirmed Teva’s B1a rating and revised Teva’s outlook to positive fro...
S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva's long-term issuer credi...
Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026
Quarterly-filed Form 13Fs allow investors to track which stocks Wall Street's savviest money managers are buying and selling. Billionaire Stanley Druckenmiller dumped his fund's stakes in AI darlings ...
Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Piper Sandler Elevates TEVA Price Target to $40 with Overweight Rating | TEVA Stock News
Piper Sandler Elevates TEVA Price Target to $40 with Overweight Rating | TEVA Stock News
Goldman Sachs Raises TEVA Price Target to $35, Maintains Buy Rating | TEVA Stock News
Goldman Sachs Raises TEVA Price Target to $35, Maintains Buy Rating | TEVA Stock News
Insider Selling: Amir Weiss Unloads $371K Of Teva Pharmaceutical Indus Stock
Disclosed on December 18, Amir Weiss , Chief Accounting Officer at Teva Pharmaceutical Indus (NYSE: TEVA), executed a substantial insider sell as per the latest SEC filing. What Happened: A Form 4 fi...
Alvotech, Teva Secures U.S. License Entry Date For Eylea Biosimilar AVT06
(RTTNews) - Alvotech (ALVO) and Teva Pharmaceutical Industries Ltd. (TEVA) have secured a U.S. license entry date for AVT06, the proposed biosimilar to Regeneron's Eylea, setting the stage for a poten...
Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S.
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
My Top 10 Portfolio Holdings for 2026
It's been another banner year on Wall Street, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite, respectively, higher by 14%, 16%, and 20% year-to-date. Although I've been a net sel...
Insider Sell: Amir Weiss Sells 12,300 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Insider Sell: Amir Weiss Sells 12,300 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today
Teva Pharmaceutical is more complex than you may realize, even though that's part of the company's plan.
Sagimet rises as licensing deal with Teva unit targets Madrigal drug
TEVA's Subsidiary Grants License to Sagimet for Innovative Drug Development
TEVA's Subsidiary Grants License to Sagimet for Innovative Drug Development
JP Morgan Raises Price Target for TEVA to $35, Maintains Overweight Rating | TEVA Stock News
JP Morgan Raises Price Target for TEVA to $35, Maintains Overweight Rating | TEVA Stock News
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?
Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.
Teva Pharmaceutical (TEVA) to Remove Over 200 Patents from FDA's Orange Book
Teva Pharmaceutical (TEVA) to Remove Over 200 Patents from FDA's Orange Book
Teva seeks removal of over 200 patents from FDA Orange Book after FTC challenge
Teva (TEVA) Requests FDA to Remove Over 200 Patent Listings
Teva (TEVA) Requests FDA to Remove Over 200 Patent Listings
TEVA Stock Rating Update: B of A Securities Raises Price Target to $32 | TEVA Stock News
TEVA Stock Rating Update: B of A Securities Raises Price Target to $32 | TEVA Stock News
TEVA Stock: Barclays Initiates Coverage with Overweight Rating | TEVA Stock News
TEVA Stock: Barclays Initiates Coverage with Overweight Rating | TEVA Stock News
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play
Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.